O. A. Karpova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
O. A. Karpova has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- G. R. Begieva
Children's Republican Clinical Hospital
3 shared publications - I. R. Zinnatullin
Republican Children’s Hospital
3 shared publications - O. G. Pyaterkina
Children’s Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
3 shared publications - A. V. Ishbuldina
Kazan State Medical University
2 shared publications - Elizaveta E. Bragina
Federal State Budgetary Scientific Institution “Research Centre for Medical Genetics” (RCMG), 1 Moskvorechye St., 115522 Moscow, Russia
2 shared publications - I. I. Zakirov
Kazan State Medical Academy
2 shared publications
Latest Publications
- 14 October 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (3)
Dynamics of lung function in patients with cystic fibrosis living in the Volga Federal District in 2017 and 2023
Cystic fibrosis (CF) is a severe hereditary disease that leads to decreased lung function. Objective. To assess the dynamics of lung function changes in CF patients living in the Volga Federal District (VFD) regions based on data from the 2017 and 2023 registries. Material and methods. Spirometry data from 375 patients from the 2017 CF patient registry and 451 patients from the 2023 registry were analyzed. Results. The median FEV1 data in VFD patients was 76.8% of the predicted value in 2017 and significantly increased to 95.3% of the predicted value in 2018. in 2023 (p<0.001). In 2017, FEV1 values in patients with CF in the Volga Federal District were not significantly different from those in the Russian Federation (75.5% of the predicted value), while in 2023, they were significantly higher than in patients in other regions of Russia (81.1% of the predicted value), p<0.001. FEV1 values increased significantly in patients from the Nizhny Novgorod Region, Orenburg Region, Perm Krai, the Republic of Tatarstan, and the Chuvash Republic. The median FVC in patients with CF from the Volga Federal District in 2017 was 85.1% of the predicted value and significantly increased to 94.0% of the predicted value in 2023 (p<0.01). In 2017, the FVC indicators in patients with CF in the Volga Federal District did not differ significantly from those in patients in the Russian Federation (86.0% of the predicted value), and in 2023 they were significantly higher than in patients in other regions of Russia (91.0% of the predicted value), p=0.037. The FVC indicators in 2023, compared with 2017, significantly increased in patients in the Nizhny Novgorod Region (p<0.001), Orenburg Region (p<0.001), Perm Krai (p=0.021), the Republic of Tatarstan (p=0.043), and the Chuvash Republic (p=0.003). In patients in the Samara Region, the indicators remained stable (p=0.331). Conclusions. FEV1 and FVC values in CF patients in both the Volga Federal District and the Russian Federation increased significantly in 2023 compared to 2017. Patient data from Volga Federal District regions where specialized CF centers were established were more informative, and patients had higher lung function values.
- 14 October 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (3)
Dynamics of lung function in patients with cystic fibrosis living in the Volga Federal District in 2017 and 2023
Cystic fibrosis (CF) is a severe hereditary disease that leads to decreased lung function. Objective. To assess the dynamics of lung function changes in CF patients living in the Volga Federal District (VFD) regions based on data from the 2017 and 2023 registries. Material and methods. Spirometry data from 375 patients from the 2017 CF patient registry and 451 patients from the 2023 registry were analyzed. Results. The median FEV1 data in VFD patients was 76.8% of the predicted value in 2017 and significantly increased to 95.3% of the predicted value in 2018. in 2023 (p<0.001). In 2017, FEV1 values in patients with CF in the Volga Federal District were not significantly different from those in the Russian Federation (75.5% of the predicted value), while in 2023, they were significantly higher than in patients in other regions of Russia (81.1% of the predicted value), p<0.001. FEV1 values increased significantly in patients from the Nizhny Novgorod Region, Orenburg Region, Perm Krai, the Republic of Tatarstan, and the Chuvash Republic. The median FVC in patients with CF from the Volga Federal District in 2017 was 85.1% of the predicted value and significantly increased to 94.0% of the predicted value in 2023 (p<0.01). In 2017, the FVC indicators in patients with CF in the Volga Federal District did not differ significantly from those in patients in the Russian Federation (86.0% of the predicted value), and in 2023 they were significantly higher than in patients in other regions of Russia (91.0% of the predicted value), p=0.037. The FVC indicators in 2023, compared with 2017, significantly increased in patients in the Nizhny Novgorod Region (p<0.001), Orenburg Region (p<0.001), Perm Krai (p=0.021), the Republic of Tatarstan (p=0.043), and the Chuvash Republic (p=0.003). In patients in the Samara Region, the indicators remained stable (p=0.331). Conclusions. FEV1 and FVC values in CF patients in both the Volga Federal District and the Russian Federation increased significantly in 2023 compared to 2017. Patient data from Volga Federal District regions where specialized CF centers were established were more informative, and patients had higher lung function values.
- 20 May 2026
- Published by Open Systems Publications in Лечащий врач
- No. 5(29)
Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan within one international nonproprietary name
Background. Due to the widespread use of targeted therapy drugs with various trade names in the treatment of cystic fibrosis, there is a need for a clinical evaluation of the results of treatment with these drugs and their tolerability and safety within the framework of routine clinical practice. Objective. The aim of the study was to present the experience of the Republic of Tatarstan in the etiopathogenetic therapy of ivacaftor + tezacaftor + elexacaftor and ivacaftor with a change of trade name within the same international nonproprietary name in pediatric patients diagnosed with cystic fibrosis, to demonstrate the clinical efficacy of this drug and its safety Conclusion. During 2025, 80 patients received etiopathogenetic therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor, including 12 children under 6 years of age, 19 aged 6 to 12 years, and 46 patients aged 12 to 18 years. The average age of patients at the start of therapy was 7.5 years. Patients with the pulmonary-intestinal form of the disease (E 84.8) prevailed – 78.3%, with a predominantly pulmonary form (E 84.0) – 21.7%. Prior to the initiation of targeted therapy and when changing the drug to a triple fixed dose combination, a comprehensive assessment of the functional capabilities of the child's body was carried out within the framework of one international nonproprietary name. Monitoring of the safety and effectiveness of treatment was carried out 14 days after the start of therapy, 1 month after, 3 months after, 6 months after, and 12 months after. Against the background of the three-component targeted therapy, patients showed an improvement in respiratory function (FEV1 and FVC), positive weight and height dynamics. When changing the drug within the same international nonproprietary name , the indicators of the function of external respiration remained at the achieved level. During the 6 months of follow-up, there were no exacerbations of cystic fibrosis that required hospitalization.
- 20 May 2026
- Published by Open Systems Publications in Лечащий врач
- No. 5(29)
Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan within one international nonproprietary name
Background. Due to the widespread use of targeted therapy drugs with various trade names in the treatment of cystic fibrosis, there is a need for a clinical evaluation of the results of treatment with these drugs and their tolerability and safety within the framework of routine clinical practice. Objective. The aim of the study was to present the experience of the Republic of Tatarstan in the etiopathogenetic therapy of ivacaftor + tezacaftor + elexacaftor and ivacaftor with a change of trade name within the same international nonproprietary name in pediatric patients diagnosed with cystic fibrosis, to demonstrate the clinical efficacy of this drug and its safety Conclusion. During 2025, 80 patients received etiopathogenetic therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor, including 12 children under 6 years of age, 19 aged 6 to 12 years, and 46 patients aged 12 to 18 years. The average age of patients at the start of therapy was 7.5 years. Patients with the pulmonary-intestinal form of the disease (E 84.8) prevailed – 78.3%, with a predominantly pulmonary form (E 84.0) – 21.7%. Prior to the initiation of targeted therapy and when changing the drug to a triple fixed dose combination, a comprehensive assessment of the functional capabilities of the child's body was carried out within the framework of one international nonproprietary name. Monitoring of the safety and effectiveness of treatment was carried out 14 days after the start of therapy, 1 month after, 3 months after, 6 months after, and 12 months after. Against the background of the three-component targeted therapy, patients showed an improvement in respiratory function (FEV1 and FVC), positive weight and height dynamics. When changing the drug within the same international nonproprietary name , the indicators of the function of external respiration remained at the achieved level. During the 6 months of follow-up, there were no exacerbations of cystic fibrosis that required hospitalization.
- 14 November 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (5) , 104-107
Clinical case of pachydermoperiostasis in pediatrician’s practice
Pachydermoperiostosis is a rare genetic disease manifested by a sharp thickening and compaction of the facial skin as a result of hyperplasia of the connective tissue of the dermis and epidermis, periostosis and deformation of the distal phalanges of the fingers and nails according to the type of «drumsticks» or «watch glasses». The disease is more common in males with an onset in adolescence. One of the reasons for the development of the primary form is a mutation in the HPGD , SLCO2A1 genes, leading to a consistently elevated level of prostaglandins E2 in the blood. The secondary form of pachydermoperiostosis is characterized mainly by bone changes and pathologies of the pulmonary and cardiovascular systems.
- 14 November 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (5) , 104-107
Clinical case of pachydermoperiostasis in pediatrician’s practice
Pachydermoperiostosis is a rare genetic disease manifested by a sharp thickening and compaction of the facial skin as a result of hyperplasia of the connective tissue of the dermis and epidermis, periostosis and deformation of the distal phalanges of the fingers and nails according to the type of «drumsticks» or «watch glasses». The disease is more common in males with an onset in adolescence. One of the reasons for the development of the primary form is a mutation in the HPGD , SLCO2A1 genes, leading to a consistently elevated level of prostaglandins E2 in the blood. The secondary form of pachydermoperiostosis is characterized mainly by bone changes and pathologies of the pulmonary and cardiovascular systems.
- Open Access
- 22 March 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (2) , 194-205
Comparative characteristics of patients with primary ciliary dyskinesia with or without Kartagener’s syndrome
Primary ciliary dyskinesia (PCD) is a rare hereditary disease, a ciliopathy that is based on a defect in the ultrastructure of the cilia of the epithelium of the respiratory tract and similar structures. All parts of the respiratory tract are affected. About half of the patients with PCD have transposition of the internal organs (Kartagener syndrome – KS).The aim was to investigate the clinical and genetic characteristics of patients with PCD with and without KS.Methods. An assessment of clinical and genetic characteristics was performed in a sample of 127 patients with PCD, who were divided into 2 groups: patients with KS (n = 60) and without KS (n = 67). The groups were compared on the basis of their medical history (according to the PICADAR scale), clinical, instrumental and laboratory data, including the results of light and video microscopy, transmission electron microscopy (TEM) and genetic testing.Results. According to the results of comparative characterization of patients with PCD with and without KS, there were similarities in the medical history, decreased lung function indices, videomicroscopy results – ciliated epithelium beating below 6 Hz, TEM – predominance of dynein arm defect. The PICADAR score was higher in the group with KS than in the group without it; congenital heart defects and renal pathology were found more frequently in patients with KS, while hearing loss and nasal polyposis were found more frequently in patients without KS. Electron microscopy revealed defects in the outer and inner dynein arms of the cilia in 50% of patients in both groups, and a tendency to lack of the central pair of microtubules in 18% of patients without KS. The following genes responsible for PCD were found in both groups: DNAH5, CFAP300 and HYDIN. DNAH5 gene variants were more common for KS patients (61.1%), while HYDIN gene variants were only found in patients with PCD without KS (15.8%).Conclusion. The identified differences may help in the diagnosis of the groups studied.
- 22 March 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (2) , 194-205
Open AccessComparative characteristics of patients with primary ciliary dyskinesia with or without Kartagener’s syndrome
Primary ciliary dyskinesia (PCD) is a rare hereditary disease, a ciliopathy that is based on a defect in the ultrastructure of the cilia of the epithelium of the respiratory tract and similar structures. All parts of the respiratory tract are affected. About half of the patients with PCD have transposition of the internal organs (Kartagener syndrome – KS).The aim was to investigate the clinical and genetic characteristics of patients with PCD with and without KS.Methods. An assessment of clinical and genetic characteristics was performed in a sample of 127 patients with PCD, who were divided into 2 groups: patients with KS (n = 60) and without KS (n = 67). The groups were compared on the basis of their medical history (according to the PICADAR scale), clinical, instrumental and laboratory data, including the results of light and video microscopy, transmission electron microscopy (TEM) and genetic testing.Results. According to the results of comparative characterization of patients with PCD with and without KS, there were similarities in the medical history, decreased lung function indices, videomicroscopy results – ciliated epithelium beating below 6 Hz, TEM – predominance of dynein arm defect. The PICADAR score was higher in the group with KS than in the group without it; congenital heart defects and renal pathology were found more frequently in patients with KS, while hearing loss and nasal polyposis were found more frequently in patients without KS. Electron microscopy revealed defects in the outer and inner dynein arms of the cilia in 50% of patients in both groups, and a tendency to lack of the central pair of microtubules in 18% of patients without KS. The following genes responsible for PCD were found in both groups: DNAH5, CFAP300 and HYDIN. DNAH5 gene variants were more common for KS patients (61.1%), while HYDIN gene variants were only found in patients with PCD without KS (15.8%).Conclusion. The identified differences may help in the diagnosis of the groups studied.
- Open Access
- 28 February 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (2) , 277-282
Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan
In connection with the introduction of targeted therapy for cystic fibrosis (CF) into clinical practice, there is a need to study the clinical effectiveness of these drugs and to record their possible side effects in children.The aim was to present the regional experience of the Republic of Tatarstan in the use of etiopathogenetic therapy (ivacaftor + tezacaftor + elexacaftor) in 41 children diagnosed with CF.Methods. Before initiation of triple therapy, a comprehensive assessment of body functions was carried out. Monitoring of safety and effectiveness was carried out at 14 days, 1 month, 3 months, 6 months, and 12 months after from the start of therapy.Results. In the first 2 weeks from the start of therapy, 10 (27%) patients reported mild side effects in the form of increased cough, sputum, and rhinorrhea, 2 (5,4%) patients had skin rashes, and 3 (8,1%) patients had elevated blood aminotransferases. One child developed encephalopathy due to arterial hypertension several months after starting therapy.Conclusion. Monitoring of the safety of the therapy over 12 months in children with CF showed a satisfactory profile. The therapy was associated with an improvement in the body functions, nutritional status, and quality of life.
- 28 February 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (2) , 277-282
Open AccessRegional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan
In connection with the introduction of targeted therapy for cystic fibrosis (CF) into clinical practice, there is a need to study the clinical effectiveness of these drugs and to record their possible side effects in children.The aim was to present the regional experience of the Republic of Tatarstan in the use of etiopathogenetic therapy (ivacaftor + tezacaftor + elexacaftor) in 41 children diagnosed with CF.Methods. Before initiation of triple therapy, a comprehensive assessment of body functions was carried out. Monitoring of safety and effectiveness was carried out at 14 days, 1 month, 3 months, 6 months, and 12 months after from the start of therapy.Results. In the first 2 weeks from the start of therapy, 10 (27%) patients reported mild side effects in the form of increased cough, sputum, and rhinorrhea, 2 (5,4%) patients had skin rashes, and 3 (8,1%) patients had elevated blood aminotransferases. One child developed encephalopathy due to arterial hypertension several months after starting therapy.Conclusion. Monitoring of the safety of the therapy over 12 months in children with CF showed a satisfactory profile. The therapy was associated with an improvement in the body functions, nutritional status, and quality of life.
- 1 January 2024
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 22 (6)
Isocaloric polymeric formula as nutritional support in children with cystic fibrosis in real clinical practice
Objective. To evaluate the tolerability, efficacy, acceptance of organoleptic properties of the specialized therapeutic product, and satisfaction with its use in children with cystic fibrosis and their parents in real clinical practice. Patients and methods. This prospective follow-up study included 14 children with cystic fibrosis (10 boys and 4 girls), mean age was 9.75 years (1.4–16.8 years). The study was conducted as part of routine clinical practice at Cystic Fibrosis Centers in Astrakhan, Kazan, and Ulyanovsk. Nutritional support was provided with an isocaloric polymeric powder formula with chocolate, strawberry, and vanilla flavors; children received an average of 1.7 servings (median 2, 1–3). At the time of inclusion in the study and after an average of 16 days (median 14, 14–21) of follow-up, body weight, height, and mid-upper arm circumference (MUAC) were assessed, and body mass index (BMI), height-for-age, BMI-for-age, and MUAC-for-age Z-scores (SDS) were calculated. In addition, some laboratory parameters (hemoglobin levels, red blood cell count, white blood cell count, ESR, total protein, albumin, and C-reactive protein levels), gastrointestinal symptoms, appetite scores at baseline and at the end of followup, and satisfaction of parents and children with the product at the end of follow-up were assessed. Prior to inclusion in the study, children were able to select the flavor of the product they would then receive by taste test. The number of servings and the need to initiate or adjust enzyme replacement therapy was determined by the physician. Results. Excellent tolerability of the product was recorded, with no adverse events, steatorrhea, and allergic reactions. Body weight (p = 0.0002), BMI (p = 0.0005), and BMI Z-score (p = 0.0005) increased statistically significantly. Children highly appreciated the taste qualities of the product. The analysis of product intake diaries confirmed 100% adherence of children to the prescribed diet therapy. A total of 85% of parents and children noted that they liked or liked very much the specialized therapeutic food product and would like to continue its use. Conclusion. This study confirmed the efficacy and excellent tolerability of the specialized therapeutic food product as nutritional support in children with cystic fibrosis. Key words: cystic fibrosis, children, adolescents, diet therapy, specialized therapeutic food products, taste test
- 1 January 2024
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 22 (6)
Isocaloric polymeric formula as nutritional support in children with cystic fibrosis in real clinical practice
Objective. To evaluate the tolerability, efficacy, acceptance of organoleptic properties of the specialized therapeutic product, and satisfaction with its use in children with cystic fibrosis and their parents in real clinical practice. Patients and methods. This prospective follow-up study included 14 children with cystic fibrosis (10 boys and 4 girls), mean age was 9.75 years (1.4–16.8 years). The study was conducted as part of routine clinical practice at Cystic Fibrosis Centers in Astrakhan, Kazan, and Ulyanovsk. Nutritional support was provided with an isocaloric polymeric powder formula with chocolate, strawberry, and vanilla flavors; children received an average of 1.7 servings (median 2, 1–3). At the time of inclusion in the study and after an average of 16 days (median 14, 14–21) of follow-up, body weight, height, and mid-upper arm circumference (MUAC) were assessed, and body mass index (BMI), height-for-age, BMI-for-age, and MUAC-for-age Z-scores (SDS) were calculated. In addition, some laboratory parameters (hemoglobin levels, red blood cell count, white blood cell count, ESR, total protein, albumin, and C-reactive protein levels), gastrointestinal symptoms, appetite scores at baseline and at the end of followup, and satisfaction of parents and children with the product at the end of follow-up were assessed. Prior to inclusion in the study, children were able to select the flavor of the product they would then receive by taste test. The number of servings and the need to initiate or adjust enzyme replacement therapy was determined by the physician. Results. Excellent tolerability of the product was recorded, with no adverse events, steatorrhea, and allergic reactions. Body weight (p = 0.0002), BMI (p = 0.0005), and BMI Z-score (p = 0.0005) increased statistically significantly. Children highly appreciated the taste qualities of the product. The analysis of product intake diaries confirmed 100% adherence of children to the prescribed diet therapy. A total of 85% of parents and children noted that they liked or liked very much the specialized therapeutic food product and would like to continue its use. Conclusion. This study confirmed the efficacy and excellent tolerability of the specialized therapeutic food product as nutritional support in children with cystic fibrosis. Key words: cystic fibrosis, children, adolescents, diet therapy, specialized therapeutic food products, taste test
- Open Access
- 13 April 2023
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 33 (2) , 198-209
Characteristics of patients with primary ciliary dyskinesia
Primary ciliary dyskinesia (PCD) (Online Mendelian Inheritance in Man - OMIM - #242650) is a rare hereditary disease, which is based on a defect in the ultrastructure of the cilia epithelium of the respiratory tract which leads to the motor function disorder. Data about health characteristics of patients with PCD in the Russian Federation are incomplete.The aim of the study was to investigate the clinical, laboratory, and instrumental characteristics of patients with PCD.Methods. The data of 90 patients (22 adults (24.4%) and 68 children (75.6%)) from several medical centers were studied. The following methods were used: medical history, spirometry, microbiological examination of the respiratory tract, video microscopic analysis of the functional activity of the nasal mucosa ciliated epithelium, transmission electron microscopy of the ciliated epithelium, and DNA testing.Results. The median age at diagnosis was 17.0 years for adults and 5.0 years for children. Kartagener syndrome was detected in 23 (27%) people, including 6 (26.0%) adults. Hearing loss was noted in 5 (26.3%) adult patients and 15 (26.8%) children. Light microscopy of the ciliated epithelium was performed in 14 (82.3%) children and 3 (17.7%) adults. In 12 patients, cilia motor activity was not registered at each of the magnifications (x 100, x 400, x 1,000). Transmission electron microscopy showed that absence ofinternal and external dynein handles (51%) and absence of internal dynein handles (17.9%) were the most common disorders. DNA testing was performed in 55 (61.2%) patients: 16 (29.1%) adults and 38 (70.9%) children. The most common genetic variants were found in the DNAH5 and HYDIN genes. Lung function was reduced in both adults and children, but a significant decrease was noted in adult patients. P. aeruginosa predominated in the culture and accounted for 21.3% (intermittent detection in 13.2%, persistent detection in 9%). It has increased resistance to antibiotics.Conclusion. The results correlate with the European data. Infection caused by P. aeruginosa with the increased resistance to antibiotics was prevalent in patienths with PCD.
- 13 April 2023
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 33 (2) , 198-209
Open AccessCharacteristics of patients with primary ciliary dyskinesia
Primary ciliary dyskinesia (PCD) (Online Mendelian Inheritance in Man - OMIM - #242650) is a rare hereditary disease, which is based on a defect in the ultrastructure of the cilia epithelium of the respiratory tract which leads to the motor function disorder. Data about health characteristics of patients with PCD in the Russian Federation are incomplete.The aim of the study was to investigate the clinical, laboratory, and instrumental characteristics of patients with PCD.Methods. The data of 90 patients (22 adults (24.4%) and 68 children (75.6%)) from several medical centers were studied. The following methods were used: medical history, spirometry, microbiological examination of the respiratory tract, video microscopic analysis of the functional activity of the nasal mucosa ciliated epithelium, transmission electron microscopy of the ciliated epithelium, and DNA testing.Results. The median age at diagnosis was 17.0 years for adults and 5.0 years for children. Kartagener syndrome was detected in 23 (27%) people, including 6 (26.0%) adults. Hearing loss was noted in 5 (26.3%) adult patients and 15 (26.8%) children. Light microscopy of the ciliated epithelium was performed in 14 (82.3%) children and 3 (17.7%) adults. In 12 patients, cilia motor activity was not registered at each of the magnifications (x 100, x 400, x 1,000). Transmission electron microscopy showed that absence ofinternal and external dynein handles (51%) and absence of internal dynein handles (17.9%) were the most common disorders. DNA testing was performed in 55 (61.2%) patients: 16 (29.1%) adults and 38 (70.9%) children. The most common genetic variants were found in the DNAH5 and HYDIN genes. Lung function was reduced in both adults and children, but a significant decrease was noted in adult patients. P. aeruginosa predominated in the culture and accounted for 21.3% (intermittent detection in 13.2%, persistent detection in 9%). It has increased resistance to antibiotics.Conclusion. The results correlate with the European data. Infection caused by P. aeruginosa with the increased resistance to antibiotics was prevalent in patienths with PCD.
- Open Access
- 12 November 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 36-41
Natural cough remedies: options for a rational choice
This work summarizes the current understanding of the mechanisms providing mucociliary clearance and their disorders in respiratory diseases. It is noted that currently the understanding of the drainage function of the respiratory tract and cough formation in bronchopulmonary pathology has significantly expanded, and therefore much attention is paid to the search for opportunities to correct these parts of pathogenesis. The use of drugs improving sputum rheology and decreasing inflammatory mucosal edema are of great importance in this aspect. The article summarizes the data on the possibilities of pathogenetic correction of respiratory disorders with the emphasis on the use of expectorants and mucolytic drugs made from herbal raw materials. For many of them a sufficiently rich clinical experience has been accumulated, and modern manufacturing techniques have significantly increased their quality and safety. The mucolytic and expectorant properties of modern herbal remedies are in many cases as good as those of synthetic drugs. An important feature of herbal remedies is that they contain a combination of many components with a complex therapeutic effect, whereby the quality of herbal remedies is ensured by the most modern manufacturing control mechanisms. The paper reflects the main therapeutic effects of herbal remedies, which depend on the plant species and are determined by their content of biologically active substances: alkaloids, glycosides (including anthraglycosides, cardiac glycosides, saponins, flavonoids), phytoncides, essential oils, coumarins, tannins, resins, etc. The results of own observations on the use of herbal remedies in routine clinical practice are presented. The high adherence of patients to the use of herbal syrups and drops based on ivy extract in the therapy of cough syndrome in adults and children is shown.
- 12 November 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 36-41
Open AccessNatural cough remedies: options for a rational choice
This work summarizes the current understanding of the mechanisms providing mucociliary clearance and their disorders in respiratory diseases. It is noted that currently the understanding of the drainage function of the respiratory tract and cough formation in bronchopulmonary pathology has significantly expanded, and therefore much attention is paid to the search for opportunities to correct these parts of pathogenesis. The use of drugs improving sputum rheology and decreasing inflammatory mucosal edema are of great importance in this aspect. The article summarizes the data on the possibilities of pathogenetic correction of respiratory disorders with the emphasis on the use of expectorants and mucolytic drugs made from herbal raw materials. For many of them a sufficiently rich clinical experience has been accumulated, and modern manufacturing techniques have significantly increased their quality and safety. The mucolytic and expectorant properties of modern herbal remedies are in many cases as good as those of synthetic drugs. An important feature of herbal remedies is that they contain a combination of many components with a complex therapeutic effect, whereby the quality of herbal remedies is ensured by the most modern manufacturing control mechanisms. The paper reflects the main therapeutic effects of herbal remedies, which depend on the plant species and are determined by their content of biologically active substances: alkaloids, glycosides (including anthraglycosides, cardiac glycosides, saponins, flavonoids), phytoncides, essential oils, coumarins, tannins, resins, etc. The results of own observations on the use of herbal remedies in routine clinical practice are presented. The high adherence of patients to the use of herbal syrups and drops based on ivy extract in the therapy of cough syndrome in adults and children is shown.